Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease

Novaliq

Status

Completed

Conditions

Dry Eye Disease

Treatments

Device: Hydrabak®

Device: NovaTears®

Study type

Interventional

Funder types

Industry

Identifiers

NT-004

Details and patient eligibility

About

Patients with mild to moderate dry eye disease will be randomized to receive either NovaTears® or Hydrabak® eye drops as control.

Enrollment

48 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Men and women aged over 18 years
History of dry eye disease for at least 3 months before the screening visit
Be able and willing to follow instructions, including participation in all study assessments and visits
Signed and dated written informed consent

Exclusion criteria

Have any clinically significant slit-lamp findings at the screening visit that may include trauma, Steven Johnson syndrome, and/or in the opinion of the investigator may interfere with study parameters
Participation in a clinical trial in the 4 weeks preceding the before the screening visit
Active ocular allergies or ocular allergies that are expected to be active during the study period
Pregnancy, planned pregnancy or lactating
Known hypersensitivity to any component of the study medication
Any medical or surgical history, disorder or disease such as acute or chronic severe organic disease